Therapeutic evaluation of rosuvastatin on lipids and endothelial cell functionalities in coronary artery lesions coinciding with hyperlipidemia.
Year: 2023
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To analyze the changes of blood lipids and endothelial cell function in patients with coronary heart disease complicated with hyperlipidemia after treatment with rosuvastatin. METHODS: A total of 120 patients with coronary heart disease and hyperlipidemia diagnosed from December 2020 to December 2021 were retrospectively included. Depending on the differences of their treatment strategies, patients were divided into the study group (60 patients were treated with rosuvastatin using the conventional treatment) and the control group (60 patients were treated with the conventional treatment). Dynamic blood lipid level monitoring was performed on the two groups of patients. The changes of cardiac function and hemorheology indexes were evaluated before and after the treatment. Analyze the difference of vascular endothelial function index between the two groups before and after the treatment. Count the occurrence of adverse reactions during the intervention period of the two groups. RESULTS: Before the treatment, there was no significant difference between the two groups in total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVDS), left ventricular end-diastolic diameter (LVEDD), fibrinogen content, plasma viscosity, nitric oxide (NO), and endothelin (ET) levels (P>0.05). At 60 days of treatment, there was no significant difference between the two groups in TC, TG, LDL-C, LVDS, and LVEDD. The fibrinogen content, plasma viscosity, and ET level were lower than those in the control group (P<0.05). The HDL-C, LVEF, and NO levels were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (8.33% vs 13.33%) (P>0.05). CONCLUSION: Resuvastatin can reduce the level of blood lipids in patients with coronary heart disease and hyperlipidemia and improve the hemorheology indexes and cardiac function of patients. Its mechanism may be related to the regulation of vascular endothelial cell function in patients with coronary heart disease.
Source: PubMed Central
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4380291172